LINKER-MM2 Trial Insights in Myeloma With Meletios-Athanasios Dimopoulos, MD

Описание: Meletios-Athanasios Dimopoulos, MD, of the National and Kapodistrian University of Athens School of Medicine, discussed the LINKER-MM2 trial presented at the 67th American Society of Hematology Annual Meeting & Exposition.

The phase 1b trial evaluated linvoseltamab, a BCMA x CD3 bispecific antibody, in combi-nation with daratumumab or isatuximab, anti-CD38 monoclonal antibodies, in 42 patients with relapsed or refractory myeloma. Patients were heavily pretreated, with three or more prior lines of therapies.

“There are recent data to indicate that the combination of an anti-BCMA bispecific mono-clonal antibody with an anti-CD38 monoclonal antibody may have enhanced activity and are worthy of evaluation in earlier lines of therapy,” Dr. Dimopoulos explained. “The ideal patient population would be patients who have received one to three prior lines of therapy and who are not exposed or sensitive to anti-CD38 monoclonal antibodies.”

The overall response rate was 87%, including a complete response rate of 53%. At the 12- month follow-up, 74% of patients remain progression free. In addition, all patients who were evaluable for measurable residual disease (MRD) achieved MRD negativity.

“We want to have a longer follow-up to evaluate in more details the progression-free survival and duration of response, as well the depth of response, because we have several patients who continue to improve their response rate,” Dr. Dimopoulos concluded.